Many shoebox-sized drugstores in Hong Kong are magnets for mainland Chinese seeking access to cutting-edge oncology and hepatitis C treatments without a prescription because they are either highly expensive or not available at home in the latest twist of cross-border healthcare buying, Bloomberg reports.
Ready for the lung cancer showdown between Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo? It's here, and way ahead of schedule.
On Oct. 10, California Gov. Jerry Brown signed a bill that prohibits the use of antibiotics for fattening up farm animals and that requires the drugs to be prescribed by licensed veterinarians. It is the most restrictive law to date in the U.S. aimed at stemming the rise of antibiotic-resistant infections.
CIMB Equities Research said last week the Trans-Pacific Partnership could negatively impact the Malaysian pharmaceutical sector, but those effects won't be felt any time soon, according to a report in The Nation.
Indian pharmaceutical firms got some good news last week when it was reported that during the period from July to September there was a 50% gain in the number of abbreviated new drug approvals (ANDAs) by the U.S. FDA, Bloomberg TV India reported.
The World Health Organization came under attack earlier this year from veterinarians concerned that it might reclassify the narcotic ketamine, thereby making it difficult to obtain.
BioMérieux's BioFire Diagnostics got an FDA OK for its rapid meningitis and encephalitis test, a feather in the company's cap as it diversifies its portfolio and ramps up business in an increasingly competitive market.
Hong Kong-listed Luye Pharma's New Drug Application to the U.S. FDA for candidate LY03004 (risperidone), aimed at treating schizophrenia and bipolar disorders, is under way without the agency requesting further clinical trials, Barron's reported, sending shares higher on Friday.
An extramarital affair has cost GVK Biosciences millions of dollars in lost opportunity and brought unwanted scrutiny of its testing procedures and a ban on the marketing of about 700 generic drugs tested at a facility where the affair began, according to a report in The Hindu newspaper.
Eli Lilly's would-be rival to Pfizer's Ibrance (palbociclib) just gained an inside track at the FDA. Regulators handed Lilly the coveted "breakthrough therapy" designation for abemaciclib, another CDK 4/6 inhibitor with big plans for carving out a niche among patients with advanced breast cancer.